Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570343 | 0.87 | CARM1 (0.46) | CARM1PRMT6AURKBMRGPRX4 | |
| SCHEMBL16128023 | 0.87 | TTR (0.52) | SLC6A4SLC6A2SLC6A3KCNH2CARM1 | |
| SCHEMBL16128005 | 0.83 | KMT2A (0.50) | CARM1PRMT6 | |
| SCHEMBL16128022 | 0.82 | PPARG (0.48) | CARM1PRMT6 | |
| SCHEMBL16128006 | 0.76 | TSHR (0.51) | CARM1MRGPRX4 | |
| SCHEMBL20101482 | 0.75 | TTR (0.49) | CARM1PRMT6MRGPRX4 | |
| SCHEMBL16128004 | 0.74 | KMT2A (0.49) | CARM1PRMT6 | |
| SCHEMBL19050227 | 0.73 | EPHX2 (0.60) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL272042 | 0.72 | CA12 (0.57) | — | |
| SCHEMBL16128014 | 0.72 | TTR (0.54) | CARM1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | SLC6A4 2186/4885SLC6A2 4367/4885SLC6A3 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.